company background image
BVS

BioventusNasdaqGS:BVS Stock Report

Market Cap

US$775.4m

7D

-1.7%

1Y

n/a

Updated

17 Oct, 2021

Data

Company Financials +
BVS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BVS Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally.

Bioventus Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioventus
Historical stock prices
Current Share PriceUS$13.64
52 Week HighUS$10.74
52 Week LowUS$19.94
Beta0
1 Month Change-1.73%
3 Month Change-16.17%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.99%

Recent News & Updates

Shareholder Returns

BVSUS Medical EquipmentUS Market
7D-1.7%0.6%2.0%
1Yn/a20.0%27.6%

Return vs Industry: Insufficient data to determine how BVS performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how BVS performed against the US Market.

Price Volatility

Is BVS's price volatile compared to industry and market?
BVS volatility
BVS Beta0
Industry Beta0.88
Market Beta1

Stable Share Price: BVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BVS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011900Ken Realihttps://www.bioventus.com

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems.

Bioventus Fundamentals Summary

How do Bioventus's earnings and revenue compare to its market cap?
BVS fundamental statistics
Market CapUS$775.43m
Earnings (TTM)-US$5.96m
Revenue (TTM)US$376.09m

2.1x

P/S Ratio

-130.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BVS income statement (TTM)
RevenueUS$376.09m
Cost of RevenueUS$104.29m
Gross ProfitUS$271.80m
ExpensesUS$277.77m
Earnings-US$5.96m

Last Reported Earnings

Jul 03, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin72.27%
Net Profit Margin-1.59%
Debt/Equity Ratio82.5%

How did BVS perform over the long term?

See historical performance and comparison

Valuation

Is Bioventus undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BVS ($13.64) is trading below our estimate of fair value ($70.28)

Significantly Below Fair Value: BVS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BVS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: BVS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BVS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BVS is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (4.3x).


Future Growth

How is Bioventus forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

46.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BVS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: BVS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BVS's is expected to become profitable in the next 3 years.

Revenue vs Market: BVS's revenue (10.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: BVS's revenue (10.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BVS's Return on Equity is forecast to be high in 3 years time (32.3%)


Past Performance

How has Bioventus performed over the past 5 years?

-150.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BVS is currently unprofitable.

Growing Profit Margin: BVS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BVS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BVS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BVS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).


Return on Equity

High ROE: BVS has a negative Return on Equity (10.92%), as it is currently unprofitable.


Financial Health

How is Bioventus's financial position?


Financial Position Analysis

Short Term Liabilities: BVS's short term assets ($290.1M) exceed its short term liabilities ($158.2M).

Long Term Liabilities: BVS's short term assets ($290.1M) exceed its long term liabilities ($269.1M).


Debt to Equity History and Analysis

Debt Level: BVS's debt to equity ratio (82.5%) is considered high.

Reducing Debt: BVS's debt to equity ratio has reduced from 110.2% to 82.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BVS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BVS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 15.1% per year.


Dividend

What is Bioventus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BVS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Ken Reali (55 yo)

1.5yrs

Tenure

US$5,460,705

Compensation

Mr. Kenneth M. Reali, also known as Ken, serves as Chief Executive Officer and Member of Board of Managers at Bioventus LLC April 20, 2020. Mr. Reali serves as Chief Executive Officer of Bioventus Inc. sin...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD5.46M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.


Leadership Team

Experienced Management: BVS's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: BVS's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BVS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: BVS only recently listed within the past 12 months.


Top Shareholders

Company Information

Bioventus Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Bioventus Inc.
  • Ticker: BVS
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$775.426m
  • Market Cap: US$560.095m
  • Shares outstanding: 56.85m
  • Website: https://www.bioventus.com

Number of Employees


Location

  • Bioventus Inc.
  • 4721 Emperor Boulevard
  • Suite 100
  • Durham
  • North Carolina
  • 27703
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 22:06
End of Day Share Price2021/10/15 00:00
Earnings2021/07/03
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.